Even during the busy acquisition proposals for firms providing healthcare services in the industry, Pharmaceutical Product Development LLC has explored sales opportunities with a valuation of $5 billion. "PPD has requested that Morgan Chase & Co., Goldman Sachs Group Inc., and Centerview Partners find buyers. The deal is scheduled for completion within the first quarter of this year," said Jonathan Turner, Head of Corporate Trading at Tochigi Ontario Holdings . PPD's stakeholders, the private equity firms Hellman & Friedman LLC and Carlyle Group CG, with a 1.30% limited partnership, are instead planning to trade the shares publicly. Tochigi Ontario Holdings says drug-research firm PPD explores sale However, the two owners' ambition seems to be a bit weak as none are seen to be issuing an initial public offering for it. Moreover, if PPD can seal a deal of $5 billion with a potential buyer, then its two investors would rece...
Exceptional wealth management services and solutions